Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockBearish
3
Neutral
3
Bullish
8
Bearish
27
Neutral
3
Bullish
16
Bearish
24
Neutral
0
Bullish
8
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Investor Presentation
Q2 FY26
Investor Presentation
Q4 FY24
Investor Presentation
Q4 FY22
Investor Presentation
Q1 FY21
Bajaj Healthcare Limited is a major pharmaceutical manufacturer specializing in APIs, finished dosage forms, and nutraceuticals. It operates 20 state-of-the-art manufacturing facilities and exports products to over 60 countries.
In FY 2025, Bajaj Healthcare achieved a total income of Rs 562.01 Cr, showcasing resilience amid challenging market conditions. The company maintains a net worth of Rs 486.39 Cr, illustrating a sound financial position.
Bajaj Healthcare's strategic acquisition of Genrx Pharmaceuticals Private Limited marks a significant growth step, reinforcing its market presence and operational capacities.
With a robust R&D pipeline, Bajaj Healthcare focuses on peptide synthesis and aims commercialization by March 2026, emphasizing its commitment to innovation and expanding global demand.
Its CDMO partnership with UK/EU clients highlights Bajaj Healthcare's strategic move to enhance international collaborations, ensuring a foothold in lucrative markets and exclusive medicinal manufacturing.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,087 Cr
High Risk
19.3
36.7
1.0
2.0
541.95
272.45
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
Bajaj Healthcare Ltd (BAJAJHCARE) is currently trading at 325.35 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Bajaj Healthcare Limited is a major pharmaceutical manufacturer specializing in APIs, finished dosage forms, and nutraceuticals. It operates 20 state-of-the-art manufacturing facilities and exports products to over 60 countries. In FY 2025, Bajaj Healthcare achieved a total income of Rs 562.01 Cr, showcasing resilience amid challenging market conditions. The company maintains a net worth of Rs 486.39 Cr, illustrating a sound financial position. Bajaj Healthcare's strategic acquisition of Genrx Pharmaceuticals Private Limited marks a significant growth step, reinforcing its market presence and operational capacities. With a robust R&D pipeline, Bajaj Healthcare focuses on peptide synthesis and aims commercialization by March 2026, emphasizing its commitment to innovation and expanding global demand. Its CDMO partnership with UK/EU clients highlights Bajaj Healthcare's strategic move to enhance international collaborations, ensuring a foothold in lucrative markets and exclusive medicinal manufacturing.
Over the past 52 weeks, Bajaj Healthcare Ltd has traded between a low of ₹272.45 and a high of ₹541.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Bajaj Healthcare Ltd has a market capitalization of approximately 1,087.47. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Bajaj Healthcare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 19.32 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,087.47 Cr, Bajaj Healthcare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Bajaj Healthcare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Bajaj Healthcare Ltd is 19.32. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The stock moved up after the company said the CDSCO’s Subject Expert Committee recommended approval to manufacture and market Cenobamate tablets.
The SEC (Neurology and Psychiatry) under CDSCO recommended that Bajaj Healthcare conduct Phase III clinical trials for Suvorexant tablets.
The record date stated in the Letter of Offer is Friday, September 5, 2025.
Bajaj Healthcare reported a standalone net loss of ₹22.85 crore in Q4 FY26, compared with a net profit of ₹11.17 crore in Q4 FY25.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
494.95 | 1,187 Cr | 27.08 | 4.31 | 0.20 | 15.92 | 21.28 | 13.63 | ||
584.55 | 1,166 Cr | 13.26 | 1.54 | 0.31 | 11.60 | 15.18 | 9.87 | ||
331.00 | 1,162 Cr | 27.03 | 15.00 | 0.00 | 51.51 | 27.98 | 10.39 | ||
325.35 | 1,087 Cr | 19.32 | 2.04 | 0.46 | 8.81 | 10.79 | 1.91 | ||
110.10 | 1,014 Cr | 611.67 | 2.77 | 0.45 | 0.42 | 2.70 | 0.19 | ||
1426.00 | 990 Cr | — | 3.07 | 0.07 | -2.54 | -1.83 | -4.45 | ||
25.43 | 972 Cr | 28.57 | 1.86 | 0.39 | 6.52 | 6.49 | -9.84 | ||
| Median: 7 Co. | — | 331.00 | 1,087 Cr | 27.05 | 2.77 | 0.31 | 8.81 | 10.79 | 1.91 |
Regulatory/Compliance Filing
Bajaj Healthcare Ltd notified exchanges that the Un‑Audited Financial Results for the quarter ended June 30, 2026 were published in Financial Express and Mumbai Lakshadweep on July 22, 2026 under Regulation 47.
Regulatory/Compliance Filing
Bajaj Healthcare Ltd informed exchanges that the unaudited financial results for the quarter ended June 30, 2026 were published in Financial Express and Mumbai Lakshadweep on July 22, 2026.
Earnings Call/Transcript
Bajaj Healthcare Ltd uploaded the audio recording of its Q1FY27 earnings call held on 21 July 2026 to discuss results for quarter ended June 30, 2026; recording is available on the company website.
Earnings Call/Transcript
Bajaj Healthcare Ltd uploaded the audio recording of the earnings call held on 2026-07-21 to discuss financial results for quarter ended 2026-06-30; link provided on company website.
Financial Results
Bajaj Healthcare Ltd reported Q1 FY27 unaudited results: Revenue Rs165.6 Cr (+11.3% YoY), EBITDA Rs29.6 Cr (+16.4% YoY), PAT Rs13.7 Cr (+15.8% YoY). Earnings call scheduled on 2026-07-21 at 16:00 IST.
Financial Results
Bajaj Healthcare announced unaudited Q1 FY27 results: Revenue Rs165.6Cr (+11.3% YoY), EBITDA Rs29.6Cr (+16.4% YoY), PAT Rs13.7Cr (+15.8% YoY). Earnings call scheduled on 2026-07-21 at 16:00 IST.
